- Home
- VTVT vs AVX Comparison
VTVT vs AVX Comparison
Compare VTVT & AVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTVT | AVX |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.0M | 119.2M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VTVT | AVX |
|---|---|---|
| Price | $33.54 | $1.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $51.33 | N/A |
| AVG Volume (30 Days) | 21.5K | ★ 177.3K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $17,000.00 | ★ $1,319,011.00 |
| Revenue This Year | N/A | $530,767.50 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 8001.54 |
| 52 Week Low | $13.46 | $1.12 |
| 52 Week High | $44.00 | $25.38 |
Technical Indicators
Market Signals| Indicator | VTVT | AVX |
|---|---|---|
| Relative Strength Index (RSI) | 46.49 | N/A |
| Support Level | $31.80 | N/A |
| Resistance Level | $41.95 | N/A |
| Average True Range (ATR) | 3.40 | 0.00 |
| MACD | -1.05 | 0.00 |
| Stochastic Oscillator | 19.44 | 0.00 |
Price Performance
Historical ComparisonAbout VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
About AVX Avax One Technology Ltd.
AVAX One Technology Ltd is a public company offering investors regulated access to the Avalanche (AVAX) ecosystem. By integrating the reliability of U.S. capital markets with the growth potential of decentralized finance, it seeks to create a bridge between traditional and digital finance. The company focuses on building a digital-asset treasury, fostering innovation, and investing in decentralized financial technologies that benefit from the Avalanche network.